CO6650353A2 - Composiciones y métodos para modular la via de señalización de wnt - Google Patents
Composiciones y métodos para modular la via de señalización de wntInfo
- Publication number
- CO6650353A2 CO6650353A2 CO12234891A CO12234891A CO6650353A2 CO 6650353 A2 CO6650353 A2 CO 6650353A2 CO 12234891 A CO12234891 A CO 12234891A CO 12234891 A CO12234891 A CO 12234891A CO 6650353 A2 CO6650353 A2 CO 6650353A2
- Authority
- CO
- Colombia
- Prior art keywords
- cancer
- modulate
- cell carcinoma
- signaling pathway
- wnt signaling
- Prior art date
Links
- 230000004156 Wnt signaling pathway Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010004146 Basal cell carcinoma Diseases 0.000 abstract 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000006168 Ewing Sarcoma Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 201000000582 Retinoblastoma Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 abstract 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000008968 osteosarcoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35956910P | 2010-06-29 | 2010-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6650353A2 true CO6650353A2 (es) | 2013-04-15 |
Family
ID=44514972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12234891A CO6650353A2 (es) | 2010-06-29 | 2012-12-27 | Composiciones y métodos para modular la via de señalización de wnt |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9181235B2 (enExample) |
| EP (1) | EP2588453B1 (enExample) |
| JP (1) | JP5778270B2 (enExample) |
| KR (1) | KR20130131290A (enExample) |
| CN (1) | CN102958917B (enExample) |
| AR (1) | AR082029A1 (enExample) |
| AU (1) | AU2011271479B2 (enExample) |
| BR (1) | BR112012033350A2 (enExample) |
| CA (1) | CA2803879A1 (enExample) |
| CL (1) | CL2012003604A1 (enExample) |
| CO (1) | CO6650353A2 (enExample) |
| CU (1) | CU20120174A7 (enExample) |
| DO (1) | DOP2012000329A (enExample) |
| EA (1) | EA201390032A1 (enExample) |
| EC (1) | ECSP13012410A (enExample) |
| ES (1) | ES2536216T3 (enExample) |
| MA (1) | MA34388B1 (enExample) |
| MX (1) | MX2012015092A (enExample) |
| NI (1) | NI201200190A (enExample) |
| PE (1) | PE20130311A1 (enExample) |
| PH (1) | PH12012502571A1 (enExample) |
| SG (1) | SG186473A1 (enExample) |
| TN (1) | TN2012000575A1 (enExample) |
| TW (1) | TW201206921A (enExample) |
| UY (1) | UY33469A (enExample) |
| WO (1) | WO2012003189A1 (enExample) |
| ZA (1) | ZA201300319B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| NZ602700A (en) | 2010-04-01 | 2014-10-31 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| UY33469A (es) * | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
| TWI567061B (zh) * | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| RU2486859C1 (ru) * | 2012-02-02 | 2013-07-10 | Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения и социального развития Российской Федерации | Способ оценки эффективности комбинированного органосохраняющего лечения первичной начальной ретинобластомы у детей |
| JP6081582B2 (ja) * | 2012-06-15 | 2017-02-15 | キュアジェニックス インコーポレイテッド | Ｗｎｔシグナリング阻害剤、組成物およびその用途としての化合物 |
| US9266959B2 (en) | 2012-10-23 | 2016-02-23 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using frizzled-binding agents |
| HK1211887A1 (en) | 2013-02-04 | 2016-06-03 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| GB201309333D0 (en) | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
| CU24425B1 (es) * | 2013-11-01 | 2019-06-04 | Novartis Ag | Amino-heteroaril-benzamidas como inhibidores de cinasa |
| AU2015329784C1 (en) * | 2014-10-08 | 2020-10-15 | Redx Pharma Plc | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signalling pathway |
| LT3204381T (lt) * | 2014-10-08 | 2022-08-25 | Redx Pharma Plc | N-piridinilo acetamido dariniai kaip wnt signalinio kelio inhibitoriai |
| CN104557862B (zh) * | 2014-12-15 | 2017-05-17 | 苏州云轩医药科技有限公司 | 具有Wnt信号通路抑制活性的杂环化合物 |
| WO2016126860A1 (en) | 2015-02-03 | 2016-08-11 | Kadmon Pharmaceuticals, Llc | Stable trientine formulations |
| US20180092866A1 (en) * | 2015-04-15 | 2018-04-05 | University Of Utah Research Foundation | Substituted n-([1,1'-biphenyl]-3-yl)-[1,1'-biphenyl]-3-carboxamide analogs as inhibitors for beta-catenin/b-cell lymphoma 9 interactions |
| US20180112273A1 (en) * | 2015-05-26 | 2018-04-26 | Curegenix Corporation | Tumor biomarkers and use thereof |
| CN107759584B (zh) * | 2016-08-16 | 2021-06-01 | 苏州云轩医药科技有限公司 | 一种具有Wnt信号通路抑制活性的氨基五元杂环化合物及其应用 |
| US10821104B2 (en) * | 2015-12-07 | 2020-11-03 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | Five-membered heterocyclic amides WNT pathway inhibitor |
| WO2017097215A1 (zh) * | 2015-12-07 | 2017-06-15 | 杭州雷索药业有限公司 | 内嵌脲类结构的wnt通路抑制剂 |
| US11542254B2 (en) | 2016-03-25 | 2023-01-03 | Universisity Of Utah Research Foundation | Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors |
| WO2018045182A1 (en) * | 2016-09-01 | 2018-03-08 | The Board Of Regents Of Hte University Of Texas System | Disubstituted and trisubtituted 1,2,3-triazoles as wnt inhibitors |
| EP3717465A1 (en) * | 2017-11-30 | 2020-10-07 | Step Pharma S.A.S. | Compounds |
| EP3717459A1 (en) | 2017-11-30 | 2020-10-07 | Step Pharma S.A.S. | Compounds |
| WO2019124603A1 (ko) * | 2017-12-22 | 2019-06-27 | 경상대학교병원 | Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물 |
| LT3762368T (lt) | 2018-03-08 | 2022-06-10 | Incyte Corporation | Aminopirazindiolio junginiai, kaip pi3k-γ inhibitoriai |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CN111662228B (zh) * | 2019-03-07 | 2023-07-28 | 中国医学科学院药物研究所 | 吡啶酮酰联芳基胺类化合物及其用途 |
| WO2020245664A1 (en) | 2019-06-04 | 2020-12-10 | Step Pharma S.A.S. | N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2h-pyran-4-carboxamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases |
| CN118234726A (zh) | 2021-11-25 | 2024-06-21 | 江苏恒瑞医药股份有限公司 | 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用 |
| EP4540228A1 (en) * | 2022-06-14 | 2025-04-23 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2003234464B2 (en) * | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| FR2847253B1 (fr) | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
| DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20080275062A1 (en) * | 2004-01-30 | 2008-11-06 | David Harold Drewry | Chemical Compounds |
| US20090099184A1 (en) * | 2006-02-16 | 2009-04-16 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| BRPI0714751A2 (pt) * | 2006-09-08 | 2014-06-24 | Genentech Inc | "antagonistas wnt , composição , ácido nucléico , vetor , célula hospedeira , artigo manufaturado , método de inibição da sinalização wnt , método para detectar a presença de uam proteina wnt , método para modular a expressão de um gene wnt alvo em uma célula , método para tratar terapeuticamente um câncer mediado por wnt e usos de uns antagonistas wnt na manufatura de um medicamento " |
| JP2011502148A (ja) | 2007-10-31 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト |
| AU2008335709A1 (en) | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
| WO2009117269A1 (en) * | 2008-03-18 | 2009-09-24 | Merck & Co., Inc. | Substituted 4-hydroxypyrimidine-5-carboxamides |
| BRPI0913119A2 (pt) * | 2008-05-27 | 2015-07-28 | Univ Texas | Inibidores de sinalização de proteína wnt |
| US8384140B2 (en) | 2008-07-29 | 2013-02-26 | International Business Machines Corporation | Structure for dual contact trench capacitor and structure thereof |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| UY33469A (es) * | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
-
2011
- 2011-06-27 UY UY0001033469A patent/UY33469A/es not_active Application Discontinuation
- 2011-06-28 SG SG2012095980A patent/SG186473A1/en unknown
- 2011-06-28 CN CN201180032354.9A patent/CN102958917B/zh active Active
- 2011-06-28 PE PE2012002648A patent/PE20130311A1/es not_active Application Discontinuation
- 2011-06-28 PH PH1/2012/502571A patent/PH12012502571A1/en unknown
- 2011-06-28 US US13/701,982 patent/US9181235B2/en active Active
- 2011-06-28 CA CA2803879A patent/CA2803879A1/en not_active Abandoned
- 2011-06-28 EP EP11733945.7A patent/EP2588453B1/en active Active
- 2011-06-28 JP JP2013518581A patent/JP5778270B2/ja active Active
- 2011-06-28 ES ES11733945.7T patent/ES2536216T3/es active Active
- 2011-06-28 WO PCT/US2011/042215 patent/WO2012003189A1/en not_active Ceased
- 2011-06-28 KR KR1020137002280A patent/KR20130131290A/ko not_active Withdrawn
- 2011-06-28 BR BR112012033350A patent/BR112012033350A2/pt not_active IP Right Cessation
- 2011-06-28 AU AU2011271479A patent/AU2011271479B2/en not_active Expired - Fee Related
- 2011-06-28 MA MA35576A patent/MA34388B1/fr unknown
- 2011-06-28 EA EA201390032A patent/EA201390032A1/ru unknown
- 2011-06-28 MX MX2012015092A patent/MX2012015092A/es not_active Application Discontinuation
- 2011-06-29 TW TW100122939A patent/TW201206921A/zh unknown
- 2011-06-29 AR ARP110102283A patent/AR082029A1/es not_active Application Discontinuation
-
2012
- 2012-12-05 TN TNP2012000575A patent/TN2012000575A1/en unknown
- 2012-12-20 CU CU2012000174A patent/CU20120174A7/es unknown
- 2012-12-20 NI NI201200190A patent/NI201200190A/es unknown
- 2012-12-20 CL CL2012003604A patent/CL2012003604A1/es unknown
- 2012-12-27 DO DO2012000329A patent/DOP2012000329A/es unknown
- 2012-12-27 CO CO12234891A patent/CO6650353A2/es unknown
-
2013
- 2013-01-14 ZA ZA2013/00319A patent/ZA201300319B/en unknown
- 2013-01-29 EC ECSP13012410 patent/ECSP13012410A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2588453B1 (en) | 2015-04-01 |
| AR082029A1 (es) | 2012-11-07 |
| EA201390032A1 (ru) | 2013-06-28 |
| SG186473A1 (en) | 2013-02-28 |
| CL2012003604A1 (es) | 2013-03-22 |
| CN102958917A (zh) | 2013-03-06 |
| ZA201300319B (en) | 2014-10-29 |
| CA2803879A1 (en) | 2012-01-05 |
| KR20130131290A (ko) | 2013-12-03 |
| MX2012015092A (es) | 2013-03-05 |
| PH12012502571A1 (en) | 2020-10-19 |
| JP5778270B2 (ja) | 2015-09-16 |
| JP2013533879A (ja) | 2013-08-29 |
| EP2588453A1 (en) | 2013-05-08 |
| ES2536216T3 (es) | 2015-05-21 |
| UY33469A (es) | 2012-01-31 |
| WO2012003189A1 (en) | 2012-01-05 |
| TW201206921A (en) | 2012-02-16 |
| AU2011271479A1 (en) | 2013-02-07 |
| AU2011271479B2 (en) | 2014-08-14 |
| US20130079328A1 (en) | 2013-03-28 |
| NI201200190A (es) | 2013-04-15 |
| DOP2012000329A (es) | 2013-07-15 |
| CN102958917B (zh) | 2014-10-08 |
| PE20130311A1 (es) | 2013-03-23 |
| ECSP13012410A (es) | 2013-03-28 |
| US9181235B2 (en) | 2015-11-10 |
| MA34388B1 (fr) | 2013-07-03 |
| BR112012033350A2 (pt) | 2016-11-29 |
| TN2012000575A1 (en) | 2014-04-01 |
| CU20120174A7 (es) | 2013-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6650353A2 (es) | Composiciones y métodos para modular la via de señalización de wnt | |
| IN2014MN01875A (enExample) | ||
| PH12015500181A1 (en) | Atx modulating agents | |
| MX377405B (es) | Compuestos para el tratamiento de cáncer. | |
| GT201300324A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
| CL2015000337A1 (es) | Compuestos derivados de 2,3-benzodiazepinas sustituidas; compuestos intermediarios; formulacion farmaceutica; uso para la profilaxis y/o terapia de trastornos tumorales tales como leucemias, carcinoma de prostata, carcinoma de mama, melanomas, entre otros y control de fertilidad masculina. | |
| CL2016001629A1 (es) | Compuestos tricíclicos como agentes anticancerígenos | |
| CL2015001508A1 (es) | Compuestos derivados de bencimidazol, antagonistas de receptores ep4; composicion farmaceutica; combinacion farmaceutica; uso para tratar y/o prevenir enfermedades tales como endometriosis, hemorragias uterinas, dismenorrea, canceres de pulmon, de intestino, de mama, de prostata, entre otros. | |
| CU24269B1 (es) | 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante | |
| CL2012003286A1 (es) | Compuestos derivados de heerociclos sustituidos, inductores de apoptosis; composicion farmaceutica; y su uso para el tratamiento de diversos cancer, tales como vejiga, cerebro, mamas, medula osea, hepatocelular, linfoma, leucemia linfoblastica, entre otros | |
| PH12015500825B1 (en) | Substituted benzene compounds | |
| CO6690792A2 (es) | Análogos de nucleotidos sustituidos | |
| NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
| UY33817A (es) | ?nuevas oxindolpirimidinas bencílicas?. | |
| JO3316B1 (ar) | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل | |
| MX2014012266A (es) | Sintesis asimetricas para compuestos espiro-oxindol utiles como agentes terapeuticos. | |
| CO7111276A2 (es) | Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met | |
| PH12014502032A1 (en) | Treatment of brain cancer | |
| MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
| MX366308B (es) | Derivados de amida como bloqueadores de ttx-s. | |
| MX360323B (es) | Derivados de pirrolopiridinona como bloqueadores de ttx-s. | |
| MX2013002155A (es) | Compuestos para el tratamiento de cancer. | |
| MX2015005732A (es) | Compuestos tricíclicos y métodos para hacer y utilizar los mismos. | |
| IN2014CN04671A (enExample) | ||
| PH12015502744A1 (en) | Bicyclic nitrogen-containing aromatic heterocyclic amide compound |